Positioning no disclosures inside 60 days, left as found
Options put/call open interest 1.40, read 2026-10-29
Ethical does not pass the values gate
Price30.31 USD
Fair value55.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-11Read Distribution33.88-10.5% to today ✓Markdown gives way to Distribution after a 20% slide in 4 weeks
2026-09-10Read Markdown42.49-28.7% to today ✓Markup gives way to Markdown after a 6% slide in 10 weeks
2026-07-02Read Markup45.15-32.9% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
United Parks & Resorts Inc. holds its Distribution at $30.31. The statistical read favours the sellers, held for 50 days.
As held on the ledger · 2026-10-23
Phase
Distribution · caution
Quantitative state
The statistical read favours the sellers, held for 50 days
Price at the screen
$30.31
Valuation
12.16 trailing · 7.03 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.25
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
89.76%
Below 33%
Interest-bearing debt is 89.8% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
6.77%
Below 49%
Money owed to the company is 6.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
United Parks & Resorts's business is in a permissible area, but its interest-bearing debt is about 90% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-30. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PRKS's ethical verdict changes
Today PRKS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 81.5% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Buy. The average target sits +48% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Theme Park Bargains Often Hide Cyclical Traps
Picture a family queuing for the orca show on a hot Florida afternoon. The ticket revenue lands, yet United Parks & Resorts still posted a three percent revenue drop while margins sit at nine percent. The forward multiple of 9.6 times looks tempting next to a calculated fair value twenty four percent higher, but leisure spending is brutally cyclical and the unknown moat offers no protection when the next downturn arrives.
We pass. Low earnings multiples on consumer cyclical names frequently mark peak profits rather than genuine value, and the analyst median target of forty six dollars barely clears the current price. Ethical screens clear, yet that alone does not turn a seasonal, weather-exposed business into a durable compounder.
Execution risk remains high if attendance softens or fuel and labour costs climb. The market has already priced in modest growth, so any slip in visitor numbers would quickly erase the apparent discount. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PRKS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Distribution$30.31+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$30.31-0.7%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading oversold. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$30.51-6.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 12% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
2026-10-18Distribution$32.47-4.2%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
2026-10-02Markdown$34.19-19.5%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44. Since the last review it its composite score rose.
2026-09-10Markdown · changed$42.49-5.8%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
2026-08-09Markup$45.11-0.1%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
2026-07-18Markup$45.15+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 3%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (10 analysts) rates it none, with a mean price target of $44.
2026-07-03Markup$45.15+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
